Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1YZ5O
|
|||
| Drug Name |
CPI-818
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | T-cell lymphoma [ICD-11: 2A90; ICD-10: C81-C86] | Phase 1 | [1] | |
| Company |
Corvus Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell-specific kinase (ITK) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Chemokine signaling pathway | |||
| T cell receptor signaling pathway | ||||
| Leukocyte transendothelial migration | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| TCR signaling in naï | ||||
| Class I PI3K signaling events | ||||
| Reactome | Generation of second messenger molecules | |||
| FCERI mediated Ca+2 mobilization | ||||
| WikiPathways | TCR Signaling Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| TCR signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03952078) A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Corvus Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.